All News

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year...

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published...

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly's cancer drug discovery research....